James W. McCollum
Known title: DirectorCIK: 0001200889
James W. McCollum's purchase track record
James W. McCollum has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/7/2025 | LENZ | $239K | -38.1% | -56.2% | +10.0% |
| 5/13/2024 | LENZ | $501K | +45.7% | +124.7% | +14.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LENZ | ▲ Buy | Open Market | 10,500 | $239K | 11/7/2025 | View on chart |
| LENZ | ▲ Buy | Open Market | 31,332 | $501K | 5/13/2024 | View on chart |
| LENZ | ▲ Buy | Grant | 95,034 | $0 | 3/21/2024 | View on chart |
| LENZ | ▲ Buy | Grant | 477,600 | $0 | 3/21/2024 | View on chart |
| LENZ | ▲ Buy | Grant | 16,633 | $250K | 3/21/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
LENZ Therapeutics faces cash concerns amid low trading levels
A recent analysis highlights LENZ Therapeutics' cash position as a key point of interest for observers. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions. While analyst targets vary widely, the focus remains on the company's financial liquidity and operational sustainability.
LENZ Therapeutics faces cash concerns amid low trading levels. A recent analysis highlights LENZ Therapeutics' cash position as a key point of interest for observers. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions. While analyst targets vary widely, the focus remains on the company's financial liquidity and operational sustainability.